Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib plus POF in advanced gastric cancer
NCT04121039Phase 2Unknown
- Sponsor
- Fujian Medical University Cancer Hospital
- Start
- Dec 2019
- Primary completion
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of Rivoceranib in gastric adenocarcinoma (2 arms), sponsored by Fujian Medical University Cancer Hospital. Primary endpoint: Progression-Free Survival Rate at 6-month. Status: unknown.
02
Drugs
Rivoceranib
03
Conditions
gastric adenocarcinoma
Beyond the preview
Go deeper on NCT04121039.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04121039.